SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes
SELLAS Life Sciences (NASDAQ: SLS), a late-stage clinical biopharmaceutical company, announced its upcoming addition to the Russell 3000® and Russell 2000® Indexes, effective June 27, 2025. This inclusion marks a significant milestone for the company, reflecting its progress in pipeline development.
The Russell 3000® Index tracks the top 3,000 U.S. public companies, while the Russell 2000® Index focuses on small-cap stocks representing about 10% of the U.S. equity market capitalization. The company is approaching key milestones, including topline Phase 2 data readout for SLS009 in acute myeloid leukemia (AML) and final analysis of the Phase 3 REGAL trial of GPS in AML.
SELLAS Life Sciences (NASDAQ: SLS), una società biofarmaceutica in fase clinica avanzata, ha annunciato la sua prossima inclusione negli indici Russell 3000® e Russell 2000®, a partire dal 27 giugno 2025. Questa inclusione rappresenta un traguardo importante per l'azienda, che riflette i progressi nello sviluppo della pipeline.
L'indice Russell 3000® monitora le prime 3.000 società pubbliche statunitensi, mentre l'indice Russell 2000® si concentra sulle azioni small-cap, che rappresentano circa il 10% della capitalizzazione di mercato azionaria degli Stati Uniti. L'azienda si avvicina a traguardi chiave, tra cui i dati principali di Fase 2 per SLS009 nella leucemia mieloide acuta (AML) e l'analisi finale dello studio di Fase 3 REGAL su GPS nell'AML.
SELLAS Life Sciences (NASDAQ: SLS), una empresa biofarmacéutica en etapa clínica avanzada, anunció su próxima inclusión en los índices Russell 3000® y Russell 2000®, efectiva a partir del 27 de junio de 2025. Esta incorporación representa un hito importante para la compañía, reflejando su progreso en el desarrollo de su cartera de productos.
El índice Russell 3000® rastrea las 3,000 principales empresas públicas de EE. UU., mientras que el índice Russell 2000® se enfoca en acciones de pequeña capitalización que representan aproximadamente el 10% de la capitalización del mercado accionario estadounidense. La compañía se acerca a hitos clave, incluyendo la lectura de datos principales de la Fase 2 para SLS009 en leucemia mieloide aguda (LMA) y el análisis final del ensayo de Fase 3 REGAL de GPS en LMA.
SELLAS Life Sciences (NASDAQ: SLS)는 후기 임상 단계의 바이오제약 회사로, 2025년 6월 27일부터 Russell 3000® 및 Russell 2000® 지수에 새로 편입될 예정임을 발표했습니다. 이번 편입은 회사의 파이프라인 개발 진전을 반영하는 중요한 이정표입니다.
Russell 3000® 지수는 미국 상장 기업 상위 3,000개를 추적하며, Russell 2000® 지수는 미국 주식 시장 시가총액의 약 10%를 차지하는 중소형주에 초점을 맞추고 있습니다. 회사는 급성 골수성 백혈병(AML) 치료제 SLS009의 2상 주요 데이터 발표와 AML 치료를 위한 GPS의 3상 REGAL 시험 최종 분석 등 주요 이정표에 다가가고 있습니다.
SELLAS Life Sciences (NASDAQ : SLS), une société biopharmaceutique en phase clinique avancée, a annoncé son intégration prochaine aux indices Russell 3000® et Russell 2000®, effective à partir du 27 juin 2025. Cette inclusion représente une étape importante pour l'entreprise, reflétant ses progrès dans le développement de son pipeline.
L'indice Russell 3000® suit les 3 000 principales entreprises publiques américaines, tandis que l'indice Russell 2000® se concentre sur les actions à petite capitalisation représentant environ 10 % de la capitalisation boursière américaine. L'entreprise approche des étapes clés, notamment la publication des données principales de la phase 2 pour SLS009 dans la leucémie myéloïde aiguë (LMA) et l'analyse finale de l'essai de phase 3 REGAL sur GPS dans la LMA.
SELLAS Life Sciences (NASDAQ: SLS), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, gab seine bevorstehende Aufnahme in die Russell 3000® und Russell 2000® Indizes bekannt, die ab dem 27. Juni 2025 wirksam wird. Diese Aufnahme stellt einen bedeutenden Meilenstein für das Unternehmen dar und spiegelt den Fortschritt in der Pipeline-Entwicklung wider.
Der Russell 3000® Index verfolgt die 3.000 größten börsennotierten US-Unternehmen, während der Russell 2000® Index sich auf Small-Cap-Aktien konzentriert, die etwa 10 % der US-Aktienmarktkapitalisierung ausmachen. Das Unternehmen nähert sich wichtigen Meilensteinen, darunter die Veröffentlichung der Topline-Daten der Phase-2-Studie zu SLS009 bei akuter myeloischer Leukämie (AML) sowie die finale Analyse der Phase-3-REGAL-Studie zu GPS bei AML.
- Inclusion in Russell 3000® and Russell 2000® Indexes increases visibility with institutional investors
- Company approaching important clinical milestones with two AML treatments
- Index membership indicates market cap growth and improved market position
- None.
Insights
SELLAS's addition to Russell indexes boosts institutional visibility as company approaches critical AML clinical trial readouts.
SELLAS's inclusion in the Russell 3000® and Russell 2000® Indexes represents a significant market structure development that typically enhances visibility among institutional investors. For small-cap biotechs like SELLAS, this inclusion often translates to improved trading liquidity and broader institutional awareness, as these widely-followed indexes are used extensively by investment managers for benchmarking and passive investment strategies.
The timing is strategically advantageous as SELLAS approaches two critical clinical milestones in their acute myeloid leukemia (AML) pipeline: the full topline Phase 2 data readout for SLS009 and the final analysis of their Phase 3 pivotal REGAL trial of GPS. These upcoming catalysts represent potential value inflection points for the company.
The Russell indexes reconstitution occurs annually, with membership lasting for one year. The Russell 3000® tracks the largest 3,000 U.S. public companies, while the Russell 2000® specifically measures small-cap performance, representing approximately
This development signals SELLAS has reached the market capitalization threshold necessary for inclusion, which could enhance their capital markets position during a critical period in their clinical development timeline. For emerging biopharmaceutical companies, increased institutional visibility can be particularly valuable when approaching significant clinical readouts that may require future capital market access.
NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Company will be added to the Russell 3000® and Russell 2000® Indexes, effective after the U.S. market close on June 27, as part of the 2025 Russell indexes annual reconstitution.
The Russell 3000® Index tracks the performance of the largest 3,000 publicly traded U.S. companies and serves as a broad benchmark for the U.S. equity market. The Russell 2000® Index, a subset of the Russell 3000®, measures the performance of the small-cap stocks and represents approximately
Membership in the indexes lasts for one year and results in automatic inclusion in appropriate growth and value style indexes. The Russell indexes are used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.
“Being added to the Russell 3000® and Russell 2000® Indexes marks an important corporate milestone for SELLAS and reflects the strong progress we continue to make advancing our pipeline and building long-term shareholder value,” said John Burns, Senior Vice President and Chief Financial Officer of SELLAS. “Inclusion in these indexes increases our visibility with institutional investors as we approach the readout of full topline Phase 2 data of SLS009 in acute myeloid leukemia (AML) and the final analysis of our Phase 3 pivotal REGAL trial of GPS in AML.”
For further information on the Russell 3000® and Russell 2000® Indexes and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.
About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (tambiciclib) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to other CDK9 inhibitors. Data suggests that SLS009 demonstrated a high response rate in AML patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases. For more information on SELLAS, please visit www.sellaslifesciences.com.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as “plan,” “expect,” “anticipate,” “may,” “might,” “will,” “should,” “project,” “believe,” “estimate,” “predict,” “potential,” “intend,” or “continue” and other words or terms of similar meaning. These statements include, without limitation, statements related to the GPS clinical development program, including the REGAL study and the timing of future milestones related thereto. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption “Risk Factors” in SELLAS’ Annual Report on Form 10-K filed on March 20, 2025 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date as of which the forward-looking statements were made.
Investor Contact
John Fraunces
Managing Director
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com
FAQ
When will SELLAS Life Sciences (SLS) be added to the Russell Indexes?
What does the Russell Indexes inclusion mean for SELLAS (SLS) stock?
What clinical trials is SELLAS Life Sciences (SLS) currently conducting?
How long will SELLAS (SLS) remain in the Russell Indexes?
